Study of a Cold Sore Patch for the Treatment of Herpes Labialis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Johnson & Johnson Consumer and Personal Products Worldwide ( Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc. )
ClinicalTrials.gov Identifier:
NCT01484067
First received: November 30, 2011
Last updated: September 27, 2012
Last verified: September 2012

November 30, 2011
September 27, 2012
November 2011
March 2012   (final data collection date for primary outcome measure)
  • Overall Condition of Cold Sore [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Taking into account the size, physical impression of the lesion and overall quality of healing, clinician will score the overall condition of the cold sore on a scale of 0-10, where 0=Best and 10=Worst.
  • Erythema [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Clinician's score on a scale of 0-10 for erythema, where 0=none and 10=most severe
  • Edema [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Clinician's score on a scale of 0-10 for edema, where 0=none and 10=most severe
  • Vesicles [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Clinician's score on a scale of 0-10 for vesicles, where 0=none and 10=most severe
  • Scab/Crust [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Clinician's score on a scale of 0-10 for scab/crust, where 0=none and 10=most severe
Same as current
Complete list of historical versions of study NCT01484067 on ClinicalTrials.gov Archive Site
  • Lesion Size [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Measurement of lesion diameter
  • Lesion Stage [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]

    Lesion Stage on a categorical scale of 1-8, as described below:

    1. = prodrome (symptoms including itching, pain, tingling, but no physical evidence of disease by inspection or by palpation)
    2. = maculae (erythema)
    3. = papule (any elevation of skin without fluid; solid raised lesion)
    4. = vesicle (blister, fluid filled or collapsed)
    5. = ulcer/eroson (moist sore/wound)
    6. = soft crust/scab
    7. = hard crust/scab
    8. = healed (normal skin with no signs or symptoms; residual postlesion skin changes such as erythema, flaking, or slight asymmetry may be present)
  • Pain [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Subject's score for unprovoked pain on a scale of 0-10, where 0=none and 10=most severe
  • Discomfort [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Subject's score for discomfort on a scale of 0-10, where 0=none and 10=most severe
  • Itching [ Time Frame: Within 10 days ] [ Designated as safety issue: No ]
    Subject's score for itching on a scale of 0-10, where 0=none and 10=most severe
  • Burning [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Subject's score for burning on a scale of 0-10, where 0=none and 10=most severe
  • Tingling [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Subject's score for tingling on a scale of 0-10, where 0=none and 10=most severe
  • Swelling [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Subject's score for swelling on a scale of 0-10, where 0=none and 10=most severe
  • Soreness/Tenderness [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Subject's score for soreness/tenderness [upon touching] on a scale of 0-10, where 0=none and 10=most severe
  • Redness [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Subject's score for redness on a scale of 0-10, where 0=none and 10=most severe
  • Blisters [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Subject's score for blisters on a scale of 0-10, where 0=none and 10=most severe
  • Scab or Crust [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Subject's score for scab or crust on a scale of 0-10, where 0=none and 10=most severe
Same as current
Not Provided
Not Provided
 
Study of a Cold Sore Patch for the Treatment of Herpes Labialis
A Randomized, Clinician-Blind, Clinical Study to Examine the Safety and Performance of Compeed© Total Care™ Cold Sore Patch With Zinc Sulfate for the Treatment of Herpes Labialis

If a person qualifies to participate in this study, they will have an equal chance of being assigned to either of two groups. One group will receive a patch that they will need to carry with them, because as soon as a cold sore starts (within 1 hour) they will need to put the patch over the sore. The other group will not get a patch, but will need to follow the other instructions anyway.

When a subject's outbreak begins, they will need to return to the study center within 24 hours. Then they will return according to the appointments given within 10 days. If the study staff sees that their sore has healed enough before 10 days, subjects will be told that they don't need to return again.

As long as subjects are in the study, they will need to answer a few simple questions every day on a card or booklet called a diary, starting the first day of their outbreak. If a subject is assigned to the patch group, they must wear the patch all the time, taking it off only to replace it (if it gets loose, dirty, or unsightly) and at the study center, when they are asked to remove the patch so the sore can be checked.

During the study subjects will be allowed to use paracetamol for pain, but no other treatments or medicine. If they use paracetamol, subjects must record it in their diary. The study will be stopped, and there will be no subject visits or treatments during the end of year holiday break. If a subject experiences an outbreak during the holiday, they may follow their usual treatment routine.

This is a two-arm, randomized, clinician-blind study. No severe adverse effects are expected to be experienced in the control group. All subjects are allowed to treat cold sore related pain with an oral analgesic - paracetamol (APAP). The use of APAP for pain will be recorded as a concomitant medication. However, subjects will be required to refrain from using any additional treatment (topical or systemic) during study participation.

Subjects randomized to treatment will be instructed to initiate the therapy within 1 hour onset of their first sign or symptom and record their assessment in the diary card (for no treatment subjects, they will only record assessments upon onset of first sign or symptom). All subjects will return to the study center for clinical assessments within 24 hours and 48 hours after onset of first sign or symptom/initiation of treatment and every other day thereafter, with a final visit at Day 10 or at the time of completion/discontinuation if before Day 10. Diaries will be completed each day, beginning upon initiation of therapy (Day 0) and continuing until study completion/discontinuation, and will include information on study product applications.

Subjects assigned to a patch treatment will wear a patch continuously on their lesion and will apply a new patch on occasions where the patch becomes loose, falls off or becomes unsightly, including at study visits to the facility where subjects will be asked to remove their patch for clinical assessments. Treatment will continue until the lesion is healed, for a maximum of 10 days. As the test period will possibly extend through the end of year holiday break, subject visits and treatments will be halted during this break. All subjects who have not initiated therapy including subjects assigned no treatment group, will be allowed to use their regular therapy for a cold sore outbreak during the holiday break.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Herpes Labialis
Device: Patch ( Compeed© Total CareTM Cold Sore Patch)
A cold sore patch containing zinc sulfate
Other Name: Compeed© Total CareTM Cold Sore Patch
  • Experimental: Patch
    At onset of signs/symptoms, subjects will apply assigned patch, and return to study center within 24 hours. Patch will be worn continuously, being replaced as needed.
    Intervention: Device: Patch ( Compeed© Total CareTM Cold Sore Patch)
  • No Intervention: No Patch
    No treatment will be initiated at onset of signs and symptoms although subject is still required to return to study center with 24 hours of onset of signs/symptoms.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
472
March 2012
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female or male 18-70 years old in good general health
  • Has a history of Herpes Labialis in the areas and with the frequency defined in the protocol.
  • Based on history, likely to experience a cold sore outbreak within next 2 to 3 months
  • Willing to provide informed consent
  • Willing to stop all other treatment of this condition and any topical products (lip balm, cosmetics, sunscreen) during test period
  • Women of child bearing potential must agree to use an adequate method of birth control (systemic birth control/intrauterine device)

Exclusion Criteria:

  • Self-reported to be pregnant, planning to become pregnant or nursing
  • Has any medical history or condition that might, per protocol or in the opinion of the investigator, compromise the subject's safety or the analysis of results.
  • Is taking or has taken within the 28 days before commencing treatment, protocol-specified medications or herbal supplements.
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT01484067
HCOWDH0003, 44-DRM-HLS-11-002
No
Johnson & Johnson Consumer and Personal Products Worldwide ( Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc. )
Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.
Not Provided
Study Director: Clare Kendall Johnson & Johsnon Consumer and Personal Products Worldwide
Johnson & Johnson Consumer and Personal Products Worldwide
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP